Mesoblast
- Market cap
- 1.81B
- P/E (TTM)i
- -31.68
- P/Bi
- 3.19
- EPSi
- -0.44
- Div yieldi
- 0.00%
- 52W posi
- 11%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 3.8 percentage points.
Institutional ownership
- Held by institutions
- 25.49% -3.80pp
- Institutions
- 109 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-08-27
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
25 filings tracked · 1 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Gregory George | Director | 20.95% |
| Silviu Itescu | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | 5.55% |
| Eric Rose | Chief Medical Officer & Executive Director | 0.52% |
| Jane Bell | Independent Non-Executive Director | 0.05% |
| Philip Krause | Non-Executive Director | 0.02% |
| William Burns | Independent Non-Executive Vice Chairman | 0.02% |
| Lynette Cobley | Director | 0.00% |
| Philip Facchina | Independent Non-Executive Director | 0.00% |
| Josaka Investments Pty Ltd. | -- | -- |
| James O’Brien | Chief Financial Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-17 | Eric Rose | Chief Medical Officer & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Philip Facchina | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | William Burns | Independent Non-Executive Vice Chairman | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Silviu Itescu | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Lynette Cobley | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Josaka Investments Pty Ltd. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jane Bell | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Philip Krause | Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Gregory George | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-15 | Gregory George | Director | Initial Statement of Beneficial | 0 | -- |
| 2025-12-22 | James O’Brien | Chief Financial Officer | Other Derivative Acquisition | +650,000 | $2.90 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:49:29 · For reference only, not investment advice and not tailored to your situation.